Capricor Therapeutics, Inc.

Good afternoon, ladies and gentlemen, and welcome to Capricorn Therapeutics' fourth quarter 2023 earnings call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star-0 for the operator. This call is being recorded on Thursday, February 29, 2024. I would now like to turn the conference over to AJ Bergman, CFO of CrapCore.

Please go ahead.

Thank you, and thank you for joining today. Before we start, I would like to state that we will be making certain forward-looking statements during today's presentation. These statements may include statements regarding, among other things, the efficacy, safety, and intended utilization of our product candidates, our future R&D plans, including our anticipated conduct and timing of preclinical and clinical studies, our enrollment of patients in our clinical studies, our plans to present or report additional data, our plans regarding regulatory filings, potential regulatory developments involving our product candidates, manufacturing capabilities, potential milestone payments, our financial position, and our possible uses of existing cash and investment resources. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the SEC, including our quarterly and annual reports. New York caution not to place undue reliance on these forward-looking statements, and we disclaim any obligation to update such statements. With that, I'll turn the call over to Linda Marban, CEO.

Thanks, AJ. Good afternoon, and thank you for joining today's call. I am encouraged with the progress we have made at Capricor in 2023 and into 2024, and today I will outline our main priorities for our lead CAP-1002 program, as well as provide a brief update on our Exosome platform technology. 2023 was a big year for CapiCorps, as we are now gearing up for biologics license application and commercialization. To that end, Capricor has assembled a team primarily focused on executing in four main areas in order to be prepared to bring our lead product, Cap 1002, to market for the treatment of DMD as expeditiously as possible. These are clinical, manufacturing, BLA readiness, and commercial preparation. I will provide an overview of each area today. First, let me provide a clinical update on our phase three, hope three pivotal trial, enrolling late stage, ambulant and non-ambulant young men with DMD across the United States. Late last year, we announced completion of enrollment in our phase three, pivotal hope three clinical trial, where we enrolled 61 subjects, randomized one-to-one to CAP-1002 or placebo. In December, We conducted a pre-specified interim futility analysis, and we were very pleased to announce that the trial was successfully deemed to not be futile with a positive recommendation to continue the trial. This analysis was based on an assessment by the Data Safety and Monitoring Board, otherwise known, of course, as the DSMB, of 30 subjects who reached the six-month time point and assessing their pull scores in a blinded fashion. This important positive outcome triggered our first milestone payment of $10 million from Nippon Shin-Yaku, further strengthening our balance sheet and extending our cash runway. Now, as you know, 2024 is a pivotal year for Capricor, as we will have data from cohort A of our phase three, hope three clinical study at the end of the year. as well as fully enroll cohort B by the second quarter of this year. To remind you, cohort B was designed at the request of FDA to demonstrate comparable efficacy of CAP 1002 from our San Diego manufacturing facility to that produced in Los Angeles. This cohort, which is designed to enroll approximately 44 subjects, is enrolling very well. In fact, enrollment has proceeded even faster than predicted, partially based on the fact that there are no current therapeutics approved and very few in clinical trials for these later stage non-ambulant patients. The primary endpoint of HOPE III is the change from baseline in the performance of the upper limb version 2.0, of course commonly known as the pull, at one year as well as various secondary skeletal and cardiac endpoints, including left ventricular ejection fraction. We have already seen efficacy in the POLE 2.0 and our Phase 2 HOPE 2 study, where the data showed a 1.8-point improvement relative to placebo and was statistically significant. Even more validating is that as shown in our Lancet paper, multiple POLE endpoints, whether specific regions or in combination, showed improvements with statistically significant changes in multiple domains. Importantly, CAP102 treated patients saw improvements in left ventricular ejection fraction, which is the gold standard measure of cardiac function. We saw a 4% improvement in treated patients with a p-value of 0.002. In addition, there were significant improvements in left ventricular and systolic and left ventricular end diastolic volume, further suggesting structural improvements in the heart. There are no approved therapeutics that we are aware of that directly address the cardiomyopathy associated with DMD. Therefore, the importance of CAP10 or 2 in this area of unmet medical need cannot be understated. We have long-term safety and efficacy data in this patient population as we are continuing to follow the patients from the HOPE II study and an open-label extension study into their fourth year, and we will plan to have the three-year results available in the second quarter of 2024. The two-year results shared last year continue to show statistically significant differences in the PULP 2.0 in the open-label extension treatment group when compared to the original rate of decline of the placebo group from HOPE-2 after one year. Further, while the natural history of DMD cardiomyopathy suggests a steady decline in cardiac function as measured by ejection fraction in the HOPE-2 open-label extension, we observed improvements in heart function in 66% of patients. The two-year results underscore the potential long-term benefits of CAP-1002 treatment in DMD. As we envision CAP-1002 as a multi-year treatment, this data set will strengthen both our potential revenue modeling and payer discussions for long-term reimbursement. DMD has rapidly become an orphan disease that has garnered a lot of attention, not only because of the terrible nature of a disease that robs children of the ability to use their muscles more often, but also because of the promise of disease modification by gene therapies and exon skipping technologies to potentially allow modification of the dystrophinopathy. Many have thought that along with exon skipping technologies, if the gene therapies are approved, there would no longer be a need for other treatments for DMG. Nothing could be further from the truth. The current gene therapy paradigm allows for a small, albeit potentially relevant, amounts of microdystrophin protein to be made. Current clinical data suggests there is an attenuation of disease progression from treatment with the gene therapy. However, we believe that it will require a multi-drug paradigm to address all of the pathological consequences of DMD, primarily inflammation and fibrosis caused by the lack of dystrophin. CAP-1002 is perfectly positioned to be a partner therapy for DMD, as the stated mechanism of action is immunomodulation and reduction in fibrosis. In fact, some of the current subjects at HOPE III are post-genes therapy, but still qualify for CAP-1002 based on the study's inclusion and exclusion criteria. CAP-1002 has a strong safety profile and is a once-a-quarter infusion that has shown to be well-tolerated. If CAP-1002 delays the disease progression, which years of data and multiple clinical trials have demonstrated, it is our hope that CAP-1002 would be a preferred treatment with gene or exon skipping therapies. Now, I would like to take a few minutes to update you on our recent FDA interactions and regulatory goals for the program over the next several quarters. As you may recall, we met with FDA last year and aligned on the design of our current phase three program with cohort A being the primary data set for the filing of the BLA and data from cohort B to be used to transition to our San Diego manufacturing facility. Now that cohort A has been fully enrolled and cohort B is heading towards full enrollment, we have continued to discuss with FDA any opportunity to expedite the filing of our BLA, keeping in mind that in order to successfully achieve BLA acceptance, a critical aspect is to meet all CMC requirements as outlined by FDA. To that end, we have successfully established a potency assay for Cap 1002 based on the mechanism of action of the product, which is acceptable to FDA for our to be marketed products and critical to the establishment of comparability between each of our manufacturing sites. As many of you know, FDA leadership has taken a great interest in helping move the field of treating DMD forward, and we continue to believe that we can work with them on a strategy to move CAP-1002 towards approval. Importantly, our San Diego manufacturing facility is now fully operational, staffed and producing doses for clinical use. Currently, we can produce enough CAP-1002 in our San Diego facility to meet and exceed NS Pharma's forecast for year one of product launch, if approved by FDA. We also have plans in place to expand our San Diego facilities operations to support a larger demand as may be necessary, but further expansion or investment would be something we will look forward to do following potential BLA acceptance. I would like to highlight that we have expended a relatively small amount of capital to build our commercial manufacturing plant. This has also allowed us to strengthen our IP portfolio with additional process and method-based patent filings and know-how. We also are able to control COGS effectively to drive margins as high as possible on revenue and or revenue shares. Importantly, we can also potentially expand our CAP 1002 program to other indications while replicating our manufacturing modules. All of this taken together puts Capricor in a good position as we prepare for our potential initial commercial product in DMD. A majority of the investment into our facility operations and personnel has gone into preparations for this endeavor, and I feel confident that we can deliver according to the timelines we have set forth. Now for our update on our commercial partnership with NS Pharma, who is already actively preparing for the potential launch of Cap 1002, assuming the data is positive, we have an accepted BLA. We continue to work closely with them as we move closer to that goal. As we have stated, subjects are continuing to report slowing of disease progression on CAP-1002, which is supported by the pull data. This positive data, combined with a strong safety profile, has led to nearly full partition and open label extension studies. Therefore, By the time of a potential BLA acceptance, we would expect to have approximately 120 patients already on CAP10 or 2 on an ongoing basis. These patients would likely become our first commercial patients. This potential revenue stream will be very supportive of a strong launch and will provide an initial commercial market for this product. Additionally, we are in the early stages of establishing a strong commercial team to support our partners at NS Pharma. Now, I'd like to briefly turn to provide an update on our exosome technology. Currently, we are pursuing two avenues of opportunity. One is our vaccine program using StealthX, our proprietary platform that is useful for engineering select proteins either inside or on the surface of the exosome. And the other is using the same basic platform, but for the development of therapeutics. 1 of our major achievements this year was being selected as part of the U. S. government's project next gen, which is slated to text vaccine candidates. For potential use and preventing coven, 19, as well as prepare for future pandemics. The structure of the arrangement with, which is otherwise known as the National Institute of allergy and infectious diseases. Is that Capricorn will provide them with manufactured vaccine. the campaign for which is underway now, and they will conduct and fully fund a phase one clinical trial. There will be three groups tested, a low dose S, a high dose S of the current strain of COVID-19, and then a bivalent candidate containing S and N, the nucleocapsid. I am pleased to inform you that we have submitted an ID to the FDA for our self X vaccine, which is currently under review. And we anticipate that once the is approved, then I will initiate the clinical trial in late 2024. I will provide more specific timelines on this program as we progress through the year. This will be the only multivalent candidate tested as far as we know, and we have high hopes for success in terms of potential safety and efficacy. If NIA finds that the vaccine meets its criteria for safety and efficacy, they may consider our program for a fully funded phase two. This opportunity is very important for Capricorn because it supports our exosome-based vaccine. And while we don't have intention to become a vaccine-focused company, it sets up the program nicely for partnering and other business development opportunities. As a reminder, the power of this technology is that it combines the speed of an mRNA vaccine with the potential efficacy of a competent protein-based vaccine. Should it work in humans as well as in preclinical animal studies, it could be a very important improvement in vaccinology. Also on the exosome front, We are in discussions with several potential partners to develop the therapeutic arm of our engineered exosome technology. The strategy involves taking the same StealthX platform and using it to target a specific tissue and then appropriately deliver a payload. Each early preclinical data suggests the strategy works, and we are looking forward to sharing more color on this important program as data becomes available. And finally, on the corporate side, We raised approximately 23 million dollars late last year in an equity offering to support our balance sheet into 2025. This strategic financing was anchored by Nippon Shin'yaku, further cementing our strong relationship and their commitment to Capricorn. As we think about moving through 2024 and into 2025, I want to remind you that our U.S. agreement with Nippon Shin'yaku comes with it an additional $90 million in potential milestone payments up to the time of approval, which are triggered upon certain regulatory-based achievements. Following potential approval, there is an additional $605 million in potential milestone payments, which will be payable to Capricor based on various sales-based targets being met. Furthermore, if we receive FDA approval for CAP 1002 for the treatment of DMD, we would be eligible to receive a priority review voucher, or the PRV, based on our previous receipt of a rare pediatric disease designation, which we retain full rights to and will look to sell to support our balance sheet. Lastly, we are in active discussions with several parties related to the European rights of Cap 1002 for GMD. Our main goal is to continue to support our balance sheet, leveraging non-dilutive partnerships to fuel Cap 1002 towards potential approval and support the ExaZone program. Overall, I want to thank you for your support. We continue to diligently manage our resources, focus our efforts on bringing Cap 1002 towards potential commercialization in the most expeditious way possible. We are very much looking forward to the next several months as we will be continuing our interactions with FDA, announcing our three-year open-label extension data, completing enrollment for cohort B, and presenting at various medical, scientific, and investor-related conferences. I will now turn the call over to AJ to run through our financials. AJ.

Thank you, Linda. This afternoon's press release provided a summary of our fourth quarter and full year 2023 financials on a GAAP basis. And you may also refer to our annual report on Form 10-K, which we expect to become available shortly. It will be accessible on the SEC website as well as our website. Turning to the financials, let me start with our cash position. We ended December 31, 2023 with cash, cash equivalents, and marketable securities of approximately $39.5 million. This excludes the $10 million milestone payment we received in January of 24 from Nippon Shin'yaku under our distribution and commercialization agreement. Based on our recent operating results and projections, we expect our cash runway to extend into the first quarter of 2025. But this expectation excludes any additional potential milestone payments under our exclusive commercialization and distribution agreements with Nippon Shinnyaku. In the fourth quarter of 23, our revenue was approximately 12.1 million compared to approximately 1 million for the fourth quarter of 2022, which was primarily attributable to the ratable recognition of the 40 million, which includes the upfront and milestone payment we have received in accordance with our U.S. commercialization and distribution agreement with Nippon Shinjuku. Excluding stock-based compensation, our research and development expenses were approximately $9.4 million for the fourth quarter of 2023, compared to approximately $6 million for the fourth quarter of 2022. The increase in expenses of $3.4 million was primarily due to increased clinical and manufacturing costs associated with our Phase III HOPE III trial. Excluding stock-based compensation, our general and administrative expenses were approximately $1.9 million for both the fourth quarter of 2023 and 2022. Net loss for the fourth quarter of 23 was approximately $800,000 compared to a net loss of $7.7 million for the fourth quarter of 2022. And net loss for the full year 23 was approximately $22.3 million compared to a net loss of approximately $29 million for the full year 2022. And with that, we will now open the lineup for questions. Operator, go ahead.

Thank you, ladies and gentlemen. We will now conduct the question and answer session. If you have a question, please press star 1 on your touch phone. If you wish to cancel your request, please press star 2. Your first question comes from Joe Pat Guinness from HC Wainwright. Your line is now open.

Hi, Linda and AJ. Thanks for taking the questions. Good afternoon. First off, so wanted to talk about your regulatory discussion. So, you know, last year you had some pretty clear frameworks that you shared with us again today about the need for cohort A and giving some manufacturing comparability from cohort B out of the San Diego facility. And you keep talking about ways to potentially expedite. So I wanted to explore that a little bit. So the first question is, is, I mean, when you look at this, you have the RMAT status, is one of the potentials here rolling BLA because you'll be able to start submitting data quicker as part of the filing and other options you might be considering?

No, always a pleasure. Thanks for the question. So, you know, I'm going to start answering by saying I've been working on this therapeutic for 19 years and where we are right now is just so staggeringly exciting to me. It's sometimes hard to express, but what has been the best part of the last few months has been the careful attention that FDA has been paying to Capricor and to Cap 1002. They recognize the positive safety and efficacy data. They've looked at the open label extension data, the HOPE II data, and they're working very closely with us. So, Yes, all options are on the table right now in terms of how to get this across the line as fast as possible. As I mentioned, leadership within CBER is aware of our program and really working very closely with us. We have RMAT. We have Rare Pediatric Disease Designation, Orphan Disease Designation. So we have a lot of the bells and whistles that will carry our program as quickly as possible into the arms of the DMD patients.

Got it. And then just curiosity for cohort B, are you strictly needing to show manufacturing comparability, or do these patients need to be follow-up for a certain time frame?

So, you know, we belt and suspense suspender the program by building in a full 1 to 1 randomized clinical trial with safety and efficacy built in. So it basically is a mirror image of cohort a, we're working with FDA on what they're going to actually ask us for what we know and what we can guarantee on is that they're willing to accept the license application on cohort a. What we're going to need from cohort B is still what we're working with them on, but it really is almost something that we've not only been prepared for, but something that comes along very naturally. So the trial cohort B, let me reemphasize, will be fully enrolled by second quarter of this year, and then we're going to be able to potentially position that as a post-marketing commitment for the program.

Got it. And then my last question, if you don't mind, and thanks for bearing with me. Absolutely. We've been talking about this for several years because, you know, we've been excited about the data. So I guess how would you portray the role of the cardiovascular data you've been accumulating, you know, through HOPE II and beyond in the evolution of your regulatory discussions and how much that may or may not be coming into play to date?

Yeah, so it's obviously 1 of the most important cornerstones of our regulatory strategy, but also in the eagerness of the community to get approval for captain to to remind you and I stated this, we saw 4% improvement and injection fraction. The goal standard of cardiac function and hope to and hope to open label extension. We didn't start measuring cardiac function until 2 years in. We'll have 3 years data in the 2nd quarter of this year. So stay tuned for that on cardiac function. But we're pretty convinced that it's going to be one of the major parts of what we're going to look for on our label. And it's, you know, the primary secondary endpoints that has been built in to hopefully both cohort A and cohort B. Got it.

Thanks for the added details, Linda.

Absolutely, Joe. Always a pleasure.

Your next question comes from Kristen Tolska from Cantor Fitzgerald.

Your line is now open.

Hi, everyone. Good afternoon. Thanks so much for taking my question.

Hi, Kristen. How are you?

I'm well. How are you doing?

Good.

So, thinking about the potential for combinations, I completely understand the need for this, but can you comment on what your expectations would be in terms of pay or support? And then gene therapy typically requires a lot more upfront timing to do the different testing, manufacturing, et cetera. Would it be your expectation that CAP-1002 would be the first therapy essentially given in this cascade? And would that be an advantage in case there is some payer pushback?

So, you know, we've had really positive feedback from payers, not just at Capricorn, but also NS Pharma has done, you know, significant work in preparing for, you know, market launch. And the way that we're understanding it is that there's going to be therapy that would be necessary for sort of management of the dystrophinopathies, right, so the exon skippers and the gene therapies. And, you know, because there's not an approved gene therapy theoretically yet, we don't really know how they're going to approach choosing those or both or whatever. But what we do know is that there needs to be a junk of therapy that would manage and I've talked about this a lot. The immunomodulation or the inflammatory response caused by the constant breakdown of protein in the body due to the mutation as well as manage the fibrosis. and help to support perhaps the framework laid down by a gene therapy or an exon skipper, which would be a healthier protein. So we are very confident that payers would find it beneficial to cover both the dystrophinopathy management strategy as well as CAP-1002 for the management of the inflammation and the fibrosis. Now, in terms of the order in which the therapeutics are given, that we would sort of have to talk to some of the KOLs. We're already starting to do some of that market research. Obviously, because we're going for our initial label for some of the later stage patients, at least based on the hope through data, we reserve the right to ask FDA to go as young as possible. You know, colloquially, we always say time is muscle. And the data has shown that once people get on Cap10 or T2, disease progression is significantly attenuated. almost immediately. So in terms of the timing of how that's done, that remains to be seen, but we're very confident that it'll be part of the overall treatment paradigm of Duchenne.

Thank you for that. And then, you know, we have seen quite a bullet to the four to five-year-olds on the Sarepta therapy, which I think underscores the unmet need here. So I wanted to ask what your thoughts are about the cadence you might see in terms of patients wanting therapy, especially because you are going after that non-ambulatory population. And then what capacity would you be able to help with, given this is half of the patients with DMD? Thanks again.

Yeah, so thank you. So, you know, we plan on swinging the door wide open in terms of what we ask for the. Benefit here, unlike many therapeutics, we're going to come into with 4 or 5 years worth of safety data, tracking children from theoretically age 10 and beyond. So we're going to open the door and see what the opportunity is. Obviously, if I had a child with, I'd want to get my child on cap center to as young as possible. There's really no downside. and potentially could, you know, even have impact on, who knows, things like steroid dosing and things that may have ultimate impacts and side effects. In terms of, you know, what we're looking for, I think that was your second question, we're looking for utilization of CAPTENDR2 as early as it becomes, you know, available to the community.

We're right there with it. Thank you. Thank you. Thank you for your time.

Your next question comes from Aydin Husainov from Leidenberg.

Your line is now open.

Good afternoon, everyone. Good afternoon, Linda, EJ. Congratulations with the progress this quarter and staying on track with the guidance with the top line in the fourth quarter, 24. I have a couple of questions. First, I wanted to ask you about the potential expansion of indication. I think you mentioned something in your remarks. The most natural expansion, I think we talked about it, was the Becker dystrophy that we see tremendous increase in value in other Becker companies. cardiomyopathy focus and focus on improving skeletal cardiac muscle function. Could you expand a little bit on any potential efforts that you're making regarding that expansion?

Yeah, thanks, Aiden, and always good to talk with you. So, you know, we've been talking about this for a while. Obviously, there's tremendous opportunities for expansion. As I mentioned, you know, the manufacturing paradigm is set. We have a potency assay that's been accepted by FDA. We understand the mechanism of action and how to make the cells, and, you know, we certainly are poised to expand our efforts. Becker is certainly 1 that's of great interest, especially since the primary manifestation later in life is the cardiomyopathy, which, as we've talked about is is 1 of the main targets that captain or 2 seems to ameliorate having said that we are. Right now, focusing almost all of our efforts on getting Cap1002 across the line for DMD. We're working on the BLA. We're working on a launch strategy, commercialization strategy. And so, indication expansion, you know, will come behind that. And we'll provide more color to you and to the market as those opportunities become available.

Okay, understood. Another question I have is regarding the hope to open extension. open-label extension trial results in the second quarter. So what are your expectations regarding this data?

Well, we have three-year data coming out in the second quarter of this year, as I said. The two-year data was extraordinary. We presented that most recently at PPMD, and then we'll be sharing some more data at the Muscular Dystrophy Association meetings next week in Orlando. We have every expectation based on the anecdotes that we hear from the subjects and their families that this trend of stabilization of disease is And attenuation of disease progression will continue. We're really looking forward to seeing the MRI data because that will be two years of sequential cardiac function data. And we have every reason to believe that we should be able to stabilize heart function as well. So, you know, we also have so many families that call us. that tell us that their sons are able to do what they weren't able to do before or they, you know, can't wait for their next infusion, can we please get in sooner because, you know, we feel it wearing off after three months. So, I'm very much looking forward to seeing that data and then ultimately sharing it with all of you.

Understood. Thank you for that. And the last question is regarding the European discussions, discussions with potential European parties. In your discussions with them, first of all, if you could give us a little bit of insight. Are these established players? Are these new players? And what are the typical questions that they ask? Which part of Capitano 2 value they are most interested in? If you could expand a little bit on this.

Yeah, so, you know, I think the European community is as interested in getting therapies across the line for DMDS as the U.S. authorities. They have a little bit different strategy in Europe. As you probably are aware, there is a little bit different way of going about it. The parties that we're talking to are some new and some established. I think we've been on the radar for several larger companies for a long time now, and with the data coming around the corner, they are paying more attention. Perhaps one of the best things is that our San Diego manufacturing facility can be EMA qualified, so we can make doses here and ship them to Europe, which is an added benefit. And in terms of the questions that we get, I think would be the typical ones, which is regulatory strategy, getting CAP2 across the line, what clinical trial work will be needed. You know, from our standpoint, it's probably going to be fairly straightforward, and we definitely look forward to making cap tenants available worldwide.

Okay.

Thank you so much, and congratulations with the progress this quarter.

Thanks, Aidan. Take care.

Ladies and gentlemen, as a reminder, should you have a question, please press star followed by the number one. There are no further questions at this time.

I'm turning it over to the management for closing remarks.

Before we conclude today's call, I want to extend my sincere gratitude to the patients, their families, the clinicians, and our partners at Nippon Shin-Yaku and NS Pharma, and of course at FDA, who continue to work with us to bring CAP-1002 closer to potential approval. Again, thank you to everyone who joined us this afternoon, and I look forward to seeing you at meetings in the future.

Ladies and gentlemen, this concludes today's conference. Thank you for joining. You may now disconnect.